Katarina Reberšek

Dr. Katarina Reberšek

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
MNMaja Preložnik Navodnik
Maja Preložnik Navodnik
KRKatarina Reberšek
Katarina Reberšek
KKKatarina Klinar
Katarina Klinar
Andrej JanežAndrej Janež
Andrej Janež
HPHelena Podgornik
Helena Podgornik
Circulating endothelial cells (CECs) and endothelial progenitor cells (EPCs) are promising markers of vascular damage and endothelial regeneration potential. We focused on the detection of CECs and EPCs using flow cytometry with regard to analytical challenges and its suitability for routine testing. As part of a clinical validation, CECs and EPCs were measured in blood samples from 83 subjects with type 1 diabetes (T1DM), evaluating an adjuvant intervention with two different antidiabetic drugs, empagliflozin (N = 28) and semaglutide (N = 29). Both groups receiving adjuvant therapy were compared with the insulin-only group (N = 26) at two time points: before the start of therapy and after 12 weeks of adjuvant therapy. All three groups were comparable regarding demographic characteristics and concomitant risk factors. Absolute and relative endothelial cell count at baseline were low and comparable to those of healthy individuals. In the group receiving empagliflozin or semaglutide, a significant increase in EPC was observed after 12 weeks of treatment. We demonstrated that EPCs have the potential to serve as markers for monitoring the efficacy of adjuvant therapy in T1DM patients. However, before their implementation in clinical practice, the flow cytometry protocol for CEC and EPC identification and quantification must be standardized.

30 January 2026 in Human Vaccines & Immunotherapeutics
Verified
Journal Article
Open access
L(Lucija Sršen (Levstek)
Lucija Sršen (Levstek)
IAIrena Auersperger
Irena Auersperger
LJLarisa Janzic
Larisa Janzic
AKAndreja Natasa Kopitar
Andreja Natasa Kopitar
KRKatarina Reberšek
Katarina Reberšek
MSMatjaž Sever
Matjaž Sever
CAR T cell therapy is a promising immunotherapy for hematologic malignancies, yet early prediction of outcomes and adverse events remains difficult, especially in small real-world cohorts. We retrospectively analyzed 14 adult patients with diffuse large B-cell lymphoma (DLBCL) treated with CAR T cells in Slovenia, assessing IL-6 increase rates and established predictive metrics including EASIX-C, CAR-HEMATOTOX, and IBPS on Day -5 (pre-lymphodepletion) and Day 0 (infusion). Contrary to our expectation, an inverse correlation was observed between the increase rate of IL-6 and the occurrence of severe cytopenias, indicating higher IL-6 increase rate leads to less severe cytopenias. The EASIX-C score showed higher predictive values when calculated on Day 0, contrary to the CAR-HEMATOTOX score, whose higher predictive values were observed on Day -5. The IBPS predictive values showed mixed results when comparing Day -5 to Day 0. We observed 50% response rate and 29% remission rate. The results highlight the utility of predictive scores, with unexpected findings on IL-6 suggesting further study is necessary.

17 December 2025 in Toxins
Verified
Journal Article
Open access
PDF file
MBMojca Dobaja Borak
Mojca Dobaja Borak
KRKatarina Reberšek
Katarina Reberšek
TKTihana Kurtović
Tihana Kurtović
ALAdrijana Leonardi
Adrijana Leonardi
Igor KrižajIgor Križaj
Igor Križaj
MBMiran Brvar
Miran Brvar
We present the case of a Vipera ammodytes ammodytes (Vaa, nose-horned viper)-bitten patient with recurrent thrombocytopenia. A 53-year-old patient envenomated by Vaa experienced three episodes of venom-dependent thrombocytopenia (4, 57 and 11 × 109/L), all of which we managed with antivenom Fab fragments. Despite these three severe episodes of thrombocytopenia within 24 h, platelet function remained intact, as demonstrated by normal thromboelastometry and aggregometry (96, 126, and 150 U) results after antivenom was administered and the platelet count normalized. Furthermore, flow cytometry showed only 0.3–1.7% expression of P-selectin on platelets, indicating that platelets did not activate but remained functional during and after thrombocytopenia. We assessed platelet function using rotational thromboelastometry, which evaluates the overall kinetics of hemostasis, including clot formation and stability. We performed aggregometry, which also reflects platelet function, only when the platelet count was within the normal range. Flow cytometry quantified P-selectin expression as a key marker of platelet activation. This case demonstrates that a component of Vaa venom can repeatedly induce venom-dependent thrombocytopenia, which is reversible by intervention, while platelet function remains intact.

29 October 2026 in Hematology Reports
Verified
Journal Article
Open access
PDF file
IZIrena Preložnik Zupan
Irena Preložnik Zupan
SDSaša Anžej Doma
Saša Anžej Doma
KRKatarina Reberšek
Katarina Reberšek
KRKarla Rener
Karla Rener
Background and Clinical Relevance: C5 inhibitors effectively control intravascular haemolysis (IVH) in paroxysmal nocturnal haemoglobinuria (PNH), but persistent extravascular haemolysis (EVH) may result in ongoing anaemia and transfusion dependence. Iptacopan, an oral complement factor B inhibitor, targets both mechanisms of haemolysis. Case Presentation: We report the 26-year clinical course of a female patient who developed PNH following severe aplastic anaemia. Despite long-term treatment with eculizumab and subsequently ravulizumab, she remained transfusion-dependent due to persistent EVH. The clinical course included three pregnancies, with successful delivery during the third following intensified eculizumab treatment and multidisciplinary management. Switching to iptacopan in 2024 resulted in normalization of haemoglobin, reticulocyte counts and lactate dehydrogenase levels, and complete transfusion independence. Conclusions: This case illustrates the evolving clinical and therapeutic challenges of aplastic anaemia-associated PNH over 26 years. It highlights the limitations of long-term C5 inhibition in controlling EVH and the potential of proximal complement inhibition to achieve sustained haematological recovery and transfusion independence.

25 December 2025 in Hematology Reports
Verified
Journal Article
Open access
PDF file
KRKatarina Reberšek
Katarina Reberšek
SDSaša Anžej Doma
Saša Anžej Doma
MSMatevz Skerget
Matevz Skerget
HPHelena Podgornik
Helena Podgornik
Background: Dendritic cells (DCs) are heterogeneous antigen-presenting cells that bridge innate and adaptive immunity. Recent classifications of hematolymphoid neoplasms highlight the complex origins of DC-related neoplasms. DCs have also been associated with the progression of multiple myeloma (MM). This report presents the case of a patient with MM in whom bone marrow analysis revealed an unusual additional clonal population of immature cells, in addition to plasmacytoid DCs, that later evolved into plasmacytoid dendritic cell proliferation associated with acute myeloid leukemia (pDC-AML). Methods: The bone marrow of a 69-year-old man with neutropenia and thrombocytopenia was examined by morphology, immunohistochemistry, flow cytometry, cytogenetics, fluorescence in situ hybridization (FISH), and next-generation sequencing (NGS). Serial assessments were performed before and during treatment with bortezomib and dexamethasone for MM, and later with daunorubicin/cytarabine for AML. Results: Initial bone marrow analysis revealed coexisting clonal plasma cells with t(11;14) and a population of CD34+/CD123+/CD45RA+ cells lacking lineage markers, in addition to pDCs, suggestive of precursor DCs rather than acute undifferentiated leukemia. Cytogenetic analysis identified a small clone with isolated del(20q), which corresponded in size to the clone of undifferentiated cells and to the clone with pathogenic variants detected by NGS in the BCOR, RUNX1, and SRSF2 genes. Myeloma therapy decreased both MM and undifferentiated cells; however, within four months, pDC-AML evolved with del(20q) and higher variant allele frequencies of the previously detected gene variants. Remission was achieved with standard AML chemotherapy. Conclusions: This case supports evidence that MM-associated immune dysfunction and bone marrow niche alterations may promote secondary myeloid malignancies independently of cytotoxic therapy. It demonstrates the earliest events in pDC-AML evolution. Furthermore, the immature immunophenotype raises the question of appropriate treatment, since a diagnosis of acute undifferentiated leukemia can be established.